Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Tempus AI, Inc. - Class A Common Stock
(NQ:
TEM
)
54.28
+0.54 (+1.00%)
Streaming Delayed Price
Updated: 1:30 PM EDT, Sep 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Tempus AI, Inc. - Class A Common Stock
Tempus Announces Real World Data Collaboration with BioNTech
September 04, 2024
From
Tempus AI, Inc.
Via
Business Wire
Tempus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
August 28, 2024
From
Tempus AI, Inc.
Via
Business Wire
MarketBeat Week in Review – 8/19 - 8/23
August 24, 2024
Stocks closed the week higher on the near certainty that the Fed will cut interest rates in September, but in the short term, all eyes are on NVDA earnings
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
Biotech Stock Soars 60% in 2024: Cathie Wood’s Bold Investment
August 23, 2024
Tempus AI is a hot healthcare stock that investors should be aware of. It is using AI to pursue "precision medicine", especially in cancer research.
Via
MarketBeat
Topics
Artificial Intelligence
ETFs
Exposures
Artificial Intelligence
NPJ Precision Oncology Publishes Tempus Study on Validation of its HLA-LOH Investigational Assay
August 08, 2024
From
Tempus AI, Inc.
Via
Business Wire
Tempus Reports Second Quarter 2024 Results
August 06, 2024
From
Tempus AI, Inc.
Via
Business Wire
Tempus Next Launches New Algorithm to Close Care Gaps in Guideline-Directed IHC Testing, Starting with HER2
August 01, 2024
From
Tempus AI, Inc.
Via
Business Wire
Tempus Announces Expanded Data and Sequencing Collaboration with Remix Therapeutics
July 30, 2024
From
Tempus AI, Inc.
Via
Business Wire
Tempus to Report Second Quarter 2024 Financial Results on August 6
July 17, 2024
From
Tempus AI, Inc.
Via
Business Wire
Tempus Expands Immuno-Oncology Portfolio with Launch of AI-enabled, Multimodal Immune Profile Algorithmic Tests
July 16, 2024
From
Tempus AI, Inc.
Via
Business Wire
Tempus Surpasses 500 Research Publications
July 10, 2024
From
Tempus AI, Inc.
Via
Business Wire
American Medical Association Grants PLA Code to Tempus Algorithmic Test, PurISTSM
July 08, 2024
From
Tempus AI, Inc.
Via
Business Wire
CMS Awards Tempus With Advanced Diagnostic Laboratory Test (ADLT) Status for its xT CDx Test
July 02, 2024
From
Tempus AI, Inc.
Via
Business Wire
Tempus Receives U.S. FDA 510(k) Clearance for Tempus ECG-AF, an AI-based Algorithm that Identifies Patients at Increased Risk of AFib
June 26, 2024
From
Tempus
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.